RxDoctor Payments Data

Ahtisham Shakoor, MD

Cardiovascular Disease · Chandler, AZNPI 1356426316

Payments from drug & device makers

$13,537in general payments, 2019–2025

Across 687 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Pfizer$1K
  • Amgen$1K
  • Heartflow, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$838
  • Boehringer Ingelheim$783
  • plus $7K from 52 others

What the payments were for

  • Consulting fees$6004%
  • Food & beverage$12,02789%
  • Education$9107%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis87$1,529
Pfizer20$1,157
Amgen84$1,135
Heartflow, Inc.5$1,049
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)49$838
Boehringer Ingelheim37$783
Johnson & Johnson40$574
Kowa Pharmaceuticals America, Inc.51$496
Merck26$486
AstraZeneca26$460
Abbott21$396
Baxter Healthcare10$354
E.r. Squibb & Sons, L.L.C.18$310
Chiesi USA, Inc.14$300
Kestra Medical Technology Services, Inc.15$293
Novo Nordisk21$274
Amarin Pharma, Inc.16$251
Boston Scientific6$221
Sanofi-aventis U.S. LLC12$215
Daiichi Sankyo Inc.13$192
Bayer12$190
Esperion Therapeutics, Inc.11$186
Bardy Diagnostics, Inc.8$165
Edwards Lifesciences6$158
Alnylam Pharmaceuticals Inc.8$137
Arbor Pharmaceuticals, Inc.11$129
Actelion Pharmaceuticals US, Inc.4$100
Cardiac Dimensions, Inc.1$97
Kiniksa Pharmaceuticals, Ltd.5$96
Abiomed4$90
Lexicon Pharmaceuticals, Inc.5$86
Atricure, Inc.2$59
Gilead3$57
Kiniksa Pharmaceuticals International, PLC2$52
Cleerly, Inc.1$51
Biotronik Inc.3$50
Tactile Systems Technology Inc2$38
Itamar Medical Inc2$35
Scpharmaceuticals Inc.2$35
Echosens North America, Inc.2$33
GE HealthCare1$31
Impulse Dynamics (USA) Inc.2$30
Lilly USA, LLC2$30
Regeneron Healthcare Solutions, Inc.2$30
Currax Pharmaceuticals LLC2$28
Livanova USA, Inc.1$27
Vivaquant Inc, Dba Rhythm Express1$27
Getinge USA Sales, LLC1$20
Acacia Pharma Inc1$19
Philips North America LLC1$18
Sensible Medical Innovations Inc1$18
Altathera Pharmaceuticals LLC1$17
Bridgebio Pharma, Inc.1$16
Inspire Medical Systems, Inc.1$15
Cranial Technologies, Inc1$14
Infobionic, Inc1$14
GSK1$14
Avinger Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,537 in reported general payments places this provider in the 75th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$860,719
Medicare patients
807
Services billed
10,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$259,071
Repatha SureclickEvolocumab139$151,206
EntrestoSacubitril/Valsartan88$140,884
JardianceEmpagliflozin70$103,896
OzempicSemaglutide43$55,852
VascepaIcosapent Ethyl56$45,579
XareltoRivaroxaban31$42,066
FarxigaDapagliflozin Propanediol23$35,086
MounjaroTirzepatide25$27,647
BrilintaTicagrelor30$23,664
Ezetimibe794$23,430
NexlizetBempedoic Acid/Ezetimibe25$19,469
LivaloPitavastatin Calcium17$12,606
Rosuvastatin Calcium643$11,716
Icosapent Ethyl19$9,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,157$259,071197 claims
NovartisEntresto$1,529$140,88488 claims
Boehringer IngelheimJardiance$783$103,89670 claims
AstraZenecaFarxiga, Brilinta$460$58,75053 claims
Novo NordiskOzempic$274$55,85243 claims
Johnson & JohnsonXarelto$574$42,06631 claims
Lilly USA, LLCMounjaro$30$27,64725 claims
Esperion Therapeutics, Inc.Nexlizet$186$19,46925 claims
Kowa Pharmaceuticals America, Inc.Livalo$496$12,60617 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$129$6,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →